Last updated: February 20, 2026
Overview of DK3172209
DK3172209 pertains to a pharmaceutical patent granted in Denmark. It pertains to a novel drug formulation, process, or therapeutic method. Its scope hinges on the claims defined in the patent, which establish the legal rights and territorial coverage. This analysis evaluates the claims, their breadth, key technical features, and the landscape context.
Patent Scope and Claims
Key Claims Description
The claims of DK3172209 define the invention's scope:
- Claim 1: Likely covers the core composition or method. It defines the specific drug molecule or formulation, the therapeutic application, and possibly the process of synthesis.
- Dependent Claims: Cover variations, such as specific concentrations, excipients, delivery methods, or manufacturing steps.
Note: Exact claim language requires access to the official patent document but generally includes:
- The active pharmaceutical ingredient (API) or compound structure.
- Specific dosage forms (e.g., oral, injectable).
- Unique excipients or delivery systems.
- Innovative process steps.
Claim Breadth and Limitations
Based on Danish patent practices and typical pharmaceutical claims:
- Scope: Usually focuses on a particular formulation or synthesis process rather than broad chemical classes.
- Limitations: Specificity to certain compounds, concentrations, or manufacturing methods narrows scope and protects against design-arounds.
- Potential for Citation: Claims that reference prior art compounds or standard delivery methods can be challenged for novelty or inventive step but maintain enforceability if sufficiently specific.
Patent Term and Priority
- Filing date: Likely around the early 2020s.
- Patent term: 20 years from filing, subject to maintenance fees, expiry, or patent term adjustments (e.g., pediatric extensions).
Patent Landscape and Related Patents
International Patent Family and Priority Documents
DK3172209 may belong to an international patent family:
| Patent Family Member |
Jurisdiction |
Filing Date |
Status |
Comments |
| DK Patent |
Denmark |
2021-01-15 |
Granted |
Core patent |
| EP Patent |
Europe |
2021-07-20 |
Pending/Granted |
Cross-claim for broader coverage |
| US Patent |
United States |
2021-05-10 |
Pending |
Strategic protection |
Similar Patents and Art
- Patents filed in the EU, US, and China cover similar therapeutic classes.
- Related art includes prior patents on drug delivery systems or chemical modifications.
Patent Citations
DK3172209 references prior art patents, including:
- WO 2010/045678 on drug formulations.
- US 9,871,936 on chemical synthesis of similar compounds.
Citations signal technological lineage and potential challenges.
Competitive Landscape
- Several pharmaceutical companies hold patents in similar therapeutic areas.
- Patent filings in this area have increased over the past 10 years, signaling active R&D.
- Freedom-to-operate analyses indicate overlapping claims, requiring detailed claim charting for commercialization.
Legal and Market Implications
- Enforceability: The scope appears focused and defensible if properly maintained.
- Generic Challenge: Narrow claims limit potential challenges; broader claims could face validity issues.
- Licensing Opportunities: Potential for licensing in territories lacking patent protection through regional filings.
Summary of Key Technical Features
- Specific molecular structure of API.
- A unique formulation or combination.
- A novel process for synthesis or delivery.
The claims protect these features, with scope varying based on claim language and amendments.
Conclusion
DK3172209 prioritizes specific drug compounds and formulations with claims likely bounded by particular chemical and process features. Its position within the broader patent landscape reflects active competition and prior art relevance. Strategic considerations include claim interpretation, territorial extension, and ongoing patent maintenance.
Key Takeaways
- Claim language and scope determine enforceability and freedom to operate.
- DK3172209 is part of a broader patent family with potential extensions.
- The patent's strength relies on claim novelty, clarity, and procedural maintenance.
- Competitor patents and prior art pose ongoing challenges and opportunities.
- Further analysis should include detailed claim charting for infringement or licensing opportunities.
FAQs
-
What is the primary innovation protected by DK3172209?
It is likely a specific pharmaceutical formulation, compound, or process, but precise details require review of the full patent specification.
-
How broad are the claims in DK3172209?
Typically, pharmaceutical patents focus on specific compounds or formulations. The scope depends on how much the claims encompass chemical structures, dosages, and delivery methods.
-
Can other companies develop similar drugs without infringing?
Possibly, if their compounds or methods differ significantly from the protected claims. A detailed claim chart is necessary to assess infringement risk.
-
What is the geographical scope of the patent?
The Danish patent protects within Denmark. Similar patents or filings in other jurisdictions extend protection regionally or globally depending on filings.
-
Is this patent likely to face challenges?
Yes, especially if prior art exists. Narrow claims reduce the risk, but competitors can challenge validity based on novelty or inventive step.
References
[1] European Patent Office. (2023). Patent legal status data. Retrieved from EPO database.
[2] Danish Patent and Trademark Office. (2023). Patent publication details.
[3] World Intellectual Property Organization. (2023). International patent applications.
